In the year when Bitcoin mining is tougher than ever before, with reduced reward after halving, one solo miner won a jackpot. In a surprising twist, the individual won against the larger players working against odds and won nearly $350k in reward. How the Solo Bitcoin Miner Made $350k With Mining? On September 7, a
The post Solo Bitcoin Miner Pulls Off $350k Block Win: Here’s How it Happened appeared first on CoinGape.
The crypto market is gearing up for a defining week with several major crypto events and macroeconomic updates lined up. From the anticipated Linea token launch and airdrop to U.S. economic data, the cryptocurrency community is watching closely to weigh where the market could head next. Major Cryptocurrency Events to Watch This week’s key crypto
The post Key Crypto Events This Week: U.S. Jobs Data, Inflation Reports, and More on Deck appeared first on CoinGape.
Strategy, previously MicroStrategy, has announced another weekly Bitcoin purchase despite failing to make the S&P 500 last week. This comes as the Bitcoin price rebounds, breaking above $112,00 today, although the MSTR stock is still down in premarket trading. Strategy Acquires 1,955 BTC For $217 Million In a press release, the company announced that it
The post Breaking: Michael Saylor’s Strategy Adds 1,955 Bitcoin Amid S&P 500 Snub; MSTR Stock Falls appeared first on CoinGape.
Somnia (SOMI) token has taken crypto investors by surprise today, with a staggering 60% surge, a new ATH, and growing market demand. Within just a week of launch, the token has experienced significant ups and downs, sparking speculation. But before that, what’s driving the uptrend today? Let’s discuss. Somnia Token Gains a Massive Rally, Price
The post Somnia (SOMI) Token Value Soars to New ATH: Here’s What’s Led to its 60% Rally Today appeared first on CoinGape.
In a massive development, Nasdaq has filed with the U.S. Securities and Exchange Commission to enable the trading of tokenized stocks on its platform. This comes as companies look to tokenize their stocks, with Galaxy Digital among the first to make this move. Nasdaq Files With SEC To List Tokenized Stocks According to a Bloomberg
The post Breaking: Nasdaq Seeks SEC Approval to List Tokenized Stocks appeared first on CoinGape.
Shares of Kenvue fell more than 10% on Friday after a report that Health Secretary Robert F. Kennedy Jr. will likely link autism to the use of the company’s pain medication Tylenol in pregnant women.
HHS will release the report that could draw that link this month, The Wall Street Journal reported on Friday.
That report will also suggest a medicine derived from folate — a water-soluble vitamin — can be used to treat symptoms of the developmental disorder in some people, according to the Journal.
In a statement, an HHS spokesperson said, “We are using gold-standard science to get to the bottom of America’s unprecedented rise in autism rates.”
“Until we release the final report, any claims about its contents are nothing more than speculation,” they added.
Tylenol could be the latest widely used and accepted treatment that Kennedy has undermined at the helm of HHS, which oversees federal health agencies that regulate drugs and other therapies. Kennedy has also taken steps to change vaccine policy in the U.S., and has amplified false claims about safe and effective shots that use mRNA technology.
Kennedy has made the disorder a key focus of HHS, pledging in April that the agency will “know what has caused the autism epidemic” by September and eliminate exposures. He also said that month that the agency has launched a “massive testing and research effort” involving hundreds of scientists worldwide that will determine the cause.
In a statement, Kenvue said it has “continuously evaluated the science and [continues] to believe there is no causal link” between the use of acetaminophen, the generic name for Tylenol, during pregnancy and autism.
The company added that the Food and Drug Administration and leading medical organizations “agree on the safety” of the drug, its use during pregnancy and the information provided on the Tylenol label.
The FDA website says the agency has not found “clear evidence” that appropriate use of acetaminophen during pregnancy causes “adverse pregnancy, birth, neurobehavioral, or developmental outcomes.” But the FDA said it advises pregnant women to speak with their health-care providers before using over-the-counter drugs.
The American College of Obstetricians and Gynecologists maintains that acetaminophen is safe during pregnancy when taken as directed and after consulting a health-care provider.
Some previous studies have suggested the drug poses risks to fetal development, and some parents have brought lawsuits claiming that they gave birth to children with autism after using it.
But a federal judge in Manhattan ruled in 2023 that some of those lawsuits lacked scientific evidence and later ended the litigation in 2024. Some research has also found no association between acetaminophen use and autism.
In a note on Friday, BNP Paribas analyst Navann Ty said the firm believes the “hurdle to proving causation [between the drug and autism] is high, particularly given that the litigation previously concluded in Kenvue’s favor.”